Centre Paul Strauss
24
11
12
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
4.2%
1 terminated/withdrawn out of 24 trials
83.3%
-3.2% vs industry average
4%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
EULAT Eradicate GBC
Role: lead
Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B
Role: lead
Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma
Role: lead
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Role: lead
Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution
Role: lead
Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI
Role: lead
Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)
Role: lead
Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study
Role: lead
Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)
Role: lead
Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer
Role: lead
Effects of Chemotherapy Treatment on Metaboreflex, Mechanoreflex, and Baroreflex Function: PROTECT-08B Study
Role: lead
Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Role: lead
Hippotherapy Teenager-pediatric Radiotherapy
Role: lead
Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy
Role: lead
Evolution of Hypofractionated Stereotactic Irradiation for Radio-Resistant Brain Metastases From D1-3-5 to D1-2-3
Role: lead
PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer
Role: lead
Quantitative Evaluation of the Breast's Morphological Variations During Radiotherapy: MorphoBreast3D
Role: lead
Study of the Decrease of Length of Stereotactic Body Radiation Therapy in Lung Cancer
Role: lead
Evolution of the Physical Condition in Treated Cancer Patients
Role: lead
Evaluation of Interest of a Systematic Screening for Oncological Supportive Care Needs
Role: lead